Matchpoint Therapeutics

Matchpoint is harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company’s proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology.

Headquarters Cambridge, MA
Pipeline Status Preclinical
Twitter @matchpointtx
LinkedIn Matchpoint Therapeutics